NCT07337317 Evaluating Stairway Designs for Individuals With Vision Impairment
| NCT ID | NCT07337317 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Alabama in Huntsville |
| Condition | Vision, Low |
| Study Type | INTERVENTIONAL |
| Enrollment | 65 participants |
| Start Date | 2026-01-22 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 65 participants in total. It began in 2026-01-22 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn if contrast frequency on step tread-edges influences foot clearance measures, a marker of fall risk, in older adults with and without visual impairments. The main questions that aim to be answered are how foot clearance measures change across different frequencies of stair contrast, and how experiences and perceptions of different stair contrast frequencies are evaluated. Researchers will compare individuals with and without visual impairments to see if contrast frequency on step tread-edges changes. Participants will attend one visit during which their vision will be measured, and they will be asked to ascend and descend laboratory stairs at different contrast frequencies. An optional second visit will entail a focus group meeting to better understand how contrast affects mobility in their home and everyday life.
Eligibility Criteria
Inclusion Criteria: 1. ≥ Contrast sensitivity log 1.6 or greater 2. travels independently in the community, including stairways \> two times/week 3. comfortable ascending and descending a stairway with rest time provided Exclusion Criteria: 4. severe rheumatologic and or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease) 5. lower-limb injuries and/or recent joint replacements (e.g., hip fracture, hip, or knee replacement within six months of study enrollment)
Contact & Investigator
Sara A Harper, PhD
PRINCIPAL INVESTIGATOR
University of Alabama in Huntsville
Frequently Asked Questions
Who can join the NCT07337317 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Vision, Low. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07337317 currently recruiting?
Yes, NCT07337317 is actively recruiting participants. Contact the research team at sah0075@uah.edu for enrollment information.
Where is the NCT07337317 trial being conducted?
This trial is being conducted at Huntsville, United States.
Who is sponsoring the NCT07337317 clinical trial?
NCT07337317 is sponsored by The University of Alabama in Huntsville. The principal investigator is Sara A Harper, PhD at University of Alabama in Huntsville. The trial plans to enroll 65 participants.